To validate whether miR124-3p and miR766-3p enhance the resistant phenotype via the CREBRF-CREB3/ATG5 and NR3C2-β-catenin/c-Myc pathways, we examined the expression of these signals in HNSCC in relation to therapeutic response. The gene discussed is MYC; the disease is head and neck squamous cell carcinoma.